Phosphate binders, vitamin D, cinacalcet : Therapeutic guidelines [Phosphatbinder, Vitamin D, Cinacalcet : Therapierichtlinien]

In the future, clinical treatment recommendations with regard to chronic kidney disease mineral and bone disorder (CKD-MBD) will have to consider cardiovascular as well as bone manifestations of secondary hyperparathyroidism and dysregulation of calcium and phosphate homeostasis. Differential therapy, including phosphate binders, active vitamin D analogues, and calcimimetics, must be tailored to the individual patient. Comorbidities, risk profiles, and also health-economic aspects will be important for guiding decision making. © 2008 Springer-Verlag.